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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease in industrial nations, characterized by fixed airway obstruction due to inflammation and thickening of the smooth muscle, deposition of extracellular matrix from activated myofibroblasts, and recruitment of inflammatory cells which secrete inflammatory mediators, reactive oxygen species and proteases. All these components of this complex pathophysiology are thought to contribute to the reduced expiratory capacity seen in COPD patients (http://www.goldcopd.org/Guidelines/guidelines-gold-summary-2 0 1 1 . h t m l .
).
Long-acting β 2 -adrenoceptor agonists (LABA) have been used as the standard of care
for COPD to provide bronchodilation and symptom relief (Donohue, 2004; Tashkin and Fabbri, 2010) . Indacaterol is a newly approved once daily LABA that shows superior bronchodilatory activity as compared to salmeterol or formoterol, but equivalency to the muscarinic antagonist tiotropium for forced expiratory volume in 1 second (FEV 1 ) (Jones et al., 2011) . Recently, the novel anti-inflammatory phosphodiesterase 4 (PDE4) inhibitor roflumilast (Daxas®; Daliresp™) has been approved in the US and EU for COPD GOLD stage 3 and 4 patients with bronchitis, where it is used as an add-on therapy to LABA treatment (Cazzola, 2010) . Six large studies ranging from 24 weeks to 1 year have demonstrated clinical efficacy for roflumilast on lung function (FEV 1 ) and acute exacerbations in COPD (Gross et al., 2010) , while no direct effect on bronchodilation has been observed. The therapeutic index for roflumilast is narrow due to dose-limiting nausea and emesis (Spina, 2008) . Attempts to develop an inhaled PDE4
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Downloaded from JPET #210997 6 inhibitor have resulted in molecules with an improved side effect profile, while still being selective and potent (Chapman et al., 2010; Nials et al., 2011; Tralau-Stewart et al., 2011) .
The combination of a bronchodilator with an anti-inflammatory agent as a treatment for COPD has been extensively discussed and is reviewed in Phillips and Salmon (Phillips and Salmon, 2012) . The ability of β 2 -adrenoceptor agonists to also have direct antiinflammatory activity has been previously described, including inhibition of histamine, arachidonic acid metabolites and TNF-α release from mast cells (Undem et al., 1988; Bissonnette and Befus, 1997; Chong et al., 1998) and on cytokine release from monocytes (Seldon et al., 2005; Donnelly et al., 2010) . Previous studies from this lab and others have shown the effects of roflumilast combined with salmeterol, formoterol or dexamethasone on lipopolysaccharide (LPS)-induced peripheral blood mononuclear cells (PBMC) cytokine production, showing additive effects for PDE4 inhibition with either a LABA or glucocorticosteroid (Seldon et al., 2005; Tannheimer et al., 2012a) , suggesting an additional anti-inflammatory effect in combination, or possible triple combination.
Additionally, the additive effects of roflumilast in combination with indacaterol on profibrotic and pro-inflammatory mediator release from transforming growth factor-β1
(TGF−β1)-treated normal human lung fibroblasts provides supporting evidence for combination therapy (Tannheimer et al., 2012b) . Figure 1 ) is a bifunctional molecule that has dual pharmacology. It contains a long acting β 2 -adrenoceptor agonist pharmacophore, covalently linked to a PDE4 inhibitor This article has not been copyedited and formatted. The final version may differ from this version. pharmacophore, that has been optimized for inhaled delivery. GS-5759 has the potential for superior anti-inflammatory activity over oral PDE4 inhibitors as topical delivery may improve the therapeutic window. Additionally, the combination of a β 2 -agonist with a PDE4 inhibitor provides the potential to elevate and maintain cellular cAMP levels, which may offer a molecular mechanism for additive or synergistic anti-inflammatory effects through elevation of a common second messenger. The anti-inflammatory and anti-fibrotic properties of GS-5759 were investigated on PBMC, neutrophils and lung fibroblasts. Evaluation of the compound as a potential component of a triple therapy approach was also evaluated by combination with the glucocorticosteroid (dexamethasone) on LPS-induced PBMC cytokine production. Additionally, relaxation of carbachol pre-contracted guinea pig smooth muscle strips was evaluated compared to the LABA indacaterol.
This article has not been copyedited and formatted. The final version may differ from this version. ICI-118551 is a potent and selective β 2 -adrenoceptor antagonist with pA 2 of 9.3 at guinea pig uterine β 2 -adrenoceptor with greater than 100-fold selectivity over β 1 -adrenoceptor and does not have partial agonist activity (Bilski et al., 1983) . Roflumilast was purchased from Kemprotec Limited (Middlesbrough, UK). Indacaterol and GS-5759 were synthesized in-house.
Compound Synthesis. The synthesis of (R)-6-((3-((4-(5-((2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)pent-1-yn-1-yl)phenyl)carbamoyl)phenyl)sulfonyl)-4-((3-methoxyphenyl)amino)-8-methylquinoline-3-carboxamide (GS-5759) was described in patent WO11143105.
PDE Enzyme Assays.
The PDE4 isozyme assays were performed based on an assay characterization described previously (Saldou et al., 1998) . The assays were optimized for each PDE4 catalytic domain isozyme at an enzyme dilution for which the concentration of product was linearly related to the time of incubation for which the velocity (nmol/min/mg total protein) was proportional to the added enzyme. PBMC were pre-incubated with ICI 118551 (10 μM) or vehicle for 60 min, followed by GS-5759 treatment alone or in combination with dexamethasone for 60 min prior to LPS (0.4 ng/mL) stimulation. Supernatants were collected after 6 h and analyzed for TNFα, interleukin 6 (IL-6), and chemokine (C-C motif) ligand 3 (CCL3) and run in a Luminex bead-based assay, according to manufacturer's instructions (EMD Millipore, Billerica, MA). Results were calculated in pg/mL based on a standard curve, and results normalized to ICI 118551 or vehicle control. The pretreatment of PBMC with ICI 118551 had no effect on LPS-stimulated cytokine production as compared to DMSO vehicle control.
Neutrophil Superoxide Anion. Human neutrophils were purified from whole blood (male non-smokers) and were pre-incubated with ICI 118551 (10 μM) or vehicle for 60 min, followed by GS-5759 treatment for 60 min prior to stimulation with formylmethionyl-leucyl-phenylalanine (fMLP) at the donor-specific EC 80 concentration (range:
200-700 nM). Superoxide release was measured with a LumiMax Superoxide Anion
Detection Kit (Agilent Technologies, Inc., Santa Clara, CA). The pretreatment of neutrophils with ICI 118551 had no effect on fMLP-stimulated superoxide anion production as compared to DMSO vehicle control. (Table 1) . In a functional assay, GS-5759 elevated intracellular cAMP in a concentration-dependent manner with an EC 50 of 8 ± 4 nM and appeared to be a full agonist at β 2 -adrenoceptor as it attained 100% of the cAMP elevation at 1 µM compared to isoproterenol standard. In a similar experiment GS-5759 elevated cAMP in a concentration-dependent manner with an EC 50 of 33 ± 20 nM at β 1-adrenoceptors. GS-5759 was a competitive, concentration-dependent inhibitor of PDE4B2 with an IC 50 of 5 ± 3 nM, in comparison to the clinically approved roflumilast which demonstrated a similar concentration-dependent inhibition of PDE4B2 of 3 ± 1 nM. GS-5759 also potently inhibited the PDE4A1, -B1 and -D2 isozymes with IC 50 of 67 ± 19, 40 ± 6, 56 ± 9 nM, respectively. The selectivity of GS-5759 against other PDE enzymes was also assessed at 1 µM, where GS-5759 inhibited PDE2A, -3B, -5, -8A1, -10A1 by less than 10%, PDE11A4 by 16 % and was without effect on PDE1B, -3A and -7A (data not shown). The IC 50 comparison to control compounds, roflumilast, GSK256066 and indacaterol are shown in Table 1 . ( Figure 2A ). When the assay was performed in the presence of an excess of the β
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adrenoceptor antagonist ICI 118551 (10 μM) (Bilski et al., 1983; Lemoine et al., 1985) , for TNFα, from 75 ± 7% to 89 ± 4% for IL-6 and from 56 ± 5% to 74 ± 5% for CCL3. 
GS-5759 Inhibition of Pro-inflammatory
Inhibition of ET-1 Production and αSMA Expression in NHLF. TGF-β1
stimulation of NHLF resulted in an increased production of the profibrotic molecule ET-1, with a change from 1 ± 0.3 to 18 ± 3 pg/mL for non-stimulated versus TGF-β1-stimulated NHLF, respectively. GS-5759 inhibited ET-1 production in a concentrationdependent manner with an IC 50 of 6 pM (C.I. 3 -9 pM) and maximum inhibition of 98 ± 1% ( Figure 4D ). Evaluation of indacaterol on ET-1 production showed an IC 50 of 61 pM (C.I. 0.04 -86 pM) and maximum inhibition of 85 ± 9%, while a 10 μM concentration of roflumilast produced very little inhibition (12 ± 4%). The IC 50 of GS-5759 was significantly different (p<0.05) to indacaterol, while the maximum level of inhibition was similar.
After TGF-β1 treatment, fibroblasts acquire a more contractile phenotype, which is characterized by expression of αSMA. Treatment of NHLF with TGF-β1 caused a 12 ± 2 fold upregulation of αSMA expression. GS-5759 exhibited a concentration-dependent inhibition of αSMA expression with an IC 50 of 7 pM (C.I. 0.07 -783) and maximum inhibition of 49 ± 3% ( Figure 4E ). Indacaterol inhibited αSMA expression with an IC 50 of 60 pM (C.I. 0.02 -230) which was not statistically different to GS-5759 and had a maximum inhibition or 42 ± 8%, ( Figure 4E ). Roflumilast alone at any concentration tested up to 10 µM failed to inhibit αSMA expression.
GS-5759 Induces pCREB in NHLF.
GS-5759 has the potential to both elevate and maintain intracellular cAMP through its activity on β 2-adrenoceptors and PDE4, respectively. GS-5759 was evaluated for its ability to phosphorylate CREB in NHLF, downstream of cAMP. GS-5759 (1 μM) was added to serum-starved NHLF over a time course of 120 min, causing an induction of pCREB that was maximal at 30-45 min after 19 association (On T 1/2 ) of 64 ± 4 and 10 ± 2 min at 300 nM and 3 µM, respectively (Table   2) . In comparison, indacaterol demonstrated a faster association rate at 300 nM with an On T 1/2 = 6 ± 0.3 min (p<0.05), but at 3 µM it had a similar On T 1/2 of 6 ± 0.3 min. The disassociation rate of GS-5759 from endogenous β 2 -adrenoceptors expressed on guinea pig airway smooth muscle strips was measured by monitoring the recovery of functional carbachol-induced contraction following wash-out of the compound from tissue baths.
GS-5759 demonstrated a time-and concentration-dependent recovery of functional carbachol-induced contractions, with Off T 1/2 times of 603 ± 61, 649 ± 54 and >720 min at 100 nM, 300 nM and 3 µM, respectively (approximate EC 30 , EC 50 and EC 80 concentrations). The Off T 1/2 times for indacaterol were 318 ± 129, 646 ± 47 and >720 min at 100 nM, 300 nM and 3 µM respectively (Table 2) . Over the concentration range used in these studies, GS-5759 appeared to have a slow functional dissociation rate from guinea pig tracheal smooth muscle, similar to indacaterol and consistent with a long duration of effect at β 2 -adrenoceptors.
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DISCUSSION
In the present study we evaluated the in vitro pharmacology of GS-5759, a novel, bifunctional molecule designed for oral inhalation delivery. GS-5759 was designed by covalently linking a PDE4 inhibitor pharmacophore with a β 2 agonist pharmacophore, with retained functional activity at both targets. GS-5759 is a potent and full agonist of β 2-adrenoceptors and is a low nanomolar inhibitor of the PDE4 enzyme. GS-5759 demonstrated potent anti-inflammatory activity in PBMC and neutrophils with apparent contributions from both the PDE4 inhibitor and β 2 agonist components. In functional studies, GS-5759 relaxed pre-contracted guinea pig airway smooth muscle strips in a concentration-dependent manner and appeared to have slow dissociation kinetics in wash-out studies.
Previous studies in our laboratory have evaluated the combined effects of the PDE4 inhibitor roflumilast and a β 2 agonist in a number of primary cell types (Tannheimer et al., 2012a; Tannheimer et al., 2012b) . In the present studies, we evaluated the combined effect of modulating both targets using the bifunctional GS-5759, with or without the β 2 antagonist ICI 118551, to differentiate the effects of both pharmacophores. In PBMC and neutrophils we observed a rightward-shift in the IC 50 in the presence of ICI 118551, suggesting the β 2 agonist component could contribute to the anti-inflammatory activity in these cell types. While we did not look at diseased cells in the present studies, the antiinflammatory activity of GS-5759 on cytokine release from LPS stimulated macrophages from COPD patients has been reported (Kaur et al., 2012) .
In similar experiments, we evaluated another relevant cell type, NHLF, which may have a different β 2 expression profile than immune cells, and here we showed that GSThis article has not been copyedited and formatted. The final version may differ from this version. 21 5759 inhibition of TNFα-driven pro-inflammatory cytokine production was equivalent to indacaterol when levels of GM-CSF, CXCL10 and CCL5 were evaluated. Roflumilast had no significant activity in this cellular assay, suggesting that under these experimental conditions, only the β 2 agonist pharmacophore was driving the inhibition seen with the GS-5759. When a different stimulation, TGF-β1, was used to induce the profibrotic molecule ET-1 and expression of αSMA, while indacaterol showed good inhibition on both mediators, the activity of GS-5759 showed an increase in potency over indacaterol.
This is a clear example of the additional effects that both components of GS-5759 can have mechanistically in relation to different stimuli, on the same cell type. This additive or cooperative effect has been demonstrated previously using separate chemical entities in the same experimental cellular assays (Tannheimer et al., 2012b) , while the effects of roflumilast as a single agent has shown little effect in our system, an observation reported by others (Togo et al., 2009; Sabatini et al., 2010) . The anti-fibrotic and antiinflammatory properties of GS-5759 on multiple cell types that may be contributing factors to the small airway disease seen in COPD patients suggests that this molecule could improve bronchodilation beyond just a direct effect on smooth muscle relaxation.
Tissue bath experiments in guinea pig airway smooth muscle suggested that GS-5759 retained a very similar potency to the parent β 2 agonist comparator indacaterol. On-and off-rate studies were performed to compare GS-5759 with indacaterol and our data indicated that at the lower concentration, indacaterol had a significantly faster On T 1/2, more rapid Off T 1/2, while at the higher concentrations the kinetics were similar for both.
The observation of the slower on-and off-rates for GS-5759 at the lower concentration tested may reflect the differences in tissue rather than receptor kinetics, although further This article has not been copyedited and formatted. The final version may differ from this version. inhibition does not have a direct effect on contractile agonist-induced contraction in airway smooth muscle strips (Underwood et al., 1998; Hatzelmann et al., 2010) .
Development of an inhaled bifunctional molecule composed of two pharmacophores that are covalently linked and can retain the ability to engage two biological targets has the potential for some distinct advantages over single molecule combination approaches.
These include enhanced lung retention times due to the increased molecular size and slower release into the systemic circulation, which could improve the therapeutic window (Robinson et al., 2011) . A single bifunctional molecule will also have matched pharmacokinetics, simplified formulation and a more straightforward regulatory path compared to a mixed fixed-dose combination (Matera et al., 2011) . For the combination of a β 2 agonist and a PDE4 inhibitor, where both act through modulation of cAMP, there is an opportunity to provide additive or synergistic interactions, as has been previously reported (Seldon et al., 2005; Tannheimer et al., 2012a; Tannheimer et al., 2012b) . This could be further enhanced, as a bifunctional molecule with a balanced optimal pharmacology could be delivered throughout the lung microenvironment, maintaining the ratio of interaction at the targets to provide maximal opportunity for their molecular interactions (Phillips and Salmon, 2012) . It should be acknowledged, however, that from This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on February 10, 2014 as DOI: 10.1124 at ASPET Journals on July 7, 2017 jpet.aspetjournals.org Downloaded from our current understanding of compartmentalised cAMP signaling, any cooperative interactions between a β 2 -adrenoceptor agonist and a PDE4 inhibitor could be cell typeand compartment-specific and that they may also act independently in many settings (Houslay, 2009 ).
Many COPD patients are treated with an inhaled combination of a LABA for symptom relief and a glucocorticosteroid which provides the anti-inflammatory activity. The magnitude of the anti-inflammatory benefit of glucocorticosteroids in COPD patients remains a matter of debate, in contrast to their efficacy in the majority of asthmatics.
However, when dosed in combination with β 2 agonists, they do improve lung function and health status in moderate to severe COPD patients (Calverley et al., 2007) . Now that Daxas® has been approved for treatment of specific COPD patient subtypes, it is of interest to understand if addition of a PDE4 inhibitor to a β 2 agonist and a glucocorticosteroid might provide additional efficacy as a triple combination. This was addressed in studies using PBMC stimulated with LPS, where GS-5759 was added in combination with the glucocorticosteroid dexamethasone. The addition of GS-5759
caused an increased inhibition of cytokine production without shifting the IC 50 for dexamethasone, showing that there is the potential for gain of anti-inflammatory activity.
The use of the bifunctional molecule with a glucocorticosteroid may exert their antiinflammatory effects through different mechanisms of action. It has been shown in bronchial epithelial cells transfected with a glucocorticoid response element (GRE) reporter that GS-5759 in combination with dexamethasone can increase activation by a 4-fold higher level over dexamethasone alone (Joshi et al., 2012) . A further recent study evaluating the individual components of a triple combination in the same reporter system This article has not been copyedited and formatted. The final version may differ from this version. suggests that direct effects on glucocorticosteroid receptor (GR) activation, or upregulation of anti-inflammatory genes independent of GR activation, could lead to enhanced anti-inflammatory gene expression to a level that can't be achieved by any of the drugs alone (Moodley et al., 2013) . Such interactions could be cell-and stimulusspecific and need to be studied further in functional cellular assays, but they underscore the potential for increased anti-inflammatory activity using such a triple combination. β 2 agonists and PDE4 inhibitors cause a downstream elevation and maintenance, respectively, of the second messenger cAMP, which leads to phosphorylation of the transcription factor CREB and activation of genes containing a cAMP responsive element (CRE) in their promoter regions (Johannessen et al., 2004) . Previously, evaluation of the mechanism of action for a β 2 agonist in combination with a PDE4 inhibitor showed an increase in CREB phosphorylation in both PBMC and NHLF (Tannheimer et al., 2012a; Tannheimer et al., 2012b) . In the present studies GS-5759 also increased phosphorylated CREB by three-fold in NHLF, and was more potent than indacaterol. These data suggest that the addition of a PDE4 inhibitor to help maintain the cAMP levels induced by a β JPET #210997 25 of this molecule, it will be important to see if this in vitro profile translates to the in vivo setting and this will be the focus of a further publication (Salmon et al., 2013) . GS-5759 is a bifunctional molecule which has the potential as a novel therapy for COPD providing both bronchodilator and anti-inflammatory activity.
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